Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES DATA VOLUME
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.1.1 PATENT LANDSCAPE
6.1.2 USPTO NUMBER
6.1.3 PATENT EXPIRY
6.1.4 EPIO NUMBER
6.1.5 PATENT STRENGTH AND QUALITY
6.1.6 PATENT CLAIMS
6.1.7 PATENT CITATIONS
6.1.8 PATENT LITIGATION AND LICENSING
6.1.9 FILE OF PATENT
6.1.10 PATENT RECEIVED CONTRIES
6.1.11 TECHNOLOGY BACKGROUND
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH SPECIALIST
6.8 OTHER KOL SNAPSHOTS
7 EPIDEMIOLOGY
7.1 INCIDENCE OF ALL BY GENDER
7.2 TREATMENT RATE
7.3 MORTALITY RATE
7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
7.5 PATIENT TREATMENT SUCCESS RATES
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 REGULATORY FRAMEWORK
9.1 REGULATORY APPROVAL PROCESS
9.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
9.3 REGULATORY APPROVAL PATHWAYS
9.4 LICENSING AND REGISTRATION
9.5 POST-MARKETING SURVEILLANCE
9.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
10 GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET, BY VACCINE TYPE
10.1 OVERVIEW
10.2 INACTIVATED VACCINES
10.3 LIVE ATTENUATED VACCINES
10.4 OTHERS
11 GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET, BY ANIMAL TYPE
11.1 OVERVIEW
11.2 CATTLE
11.2.1 HOLSTEIN
11.2.1.1. INACTIVATED VACCINES
11.2.1.2. LIVE ATTENUATED VACCINES
11.2.1.3. OTHERS
11.2.2 ANGUS
11.2.2.1. INACTIVATED VACCINES
11.2.2.2. LIVE ATTENUATED VACCINES
11.2.2.3. OTHERS
11.2.3 HEREFORD
11.2.3.1. INACTIVATED VACCINES
11.2.3.2. LIVE ATTENUATED VACCINES
11.2.3.3. OTHERS
11.2.4 BRAHMAN
11.2.4.1. INACTIVATED VACCINES
11.2.4.2. LIVE ATTENUATED VACCINES
11.2.4.3. OTHERS
11.2.5 OTHERS
11.3 WATER BUFFALO
11.3.1 INACTIVATED VACCINES
11.3.2 LIVE ATTENUATED VACCINES
11.3.3 OTHERS
11.4 OTHERS
12 GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET, BY PACKAGING
12.1 OVERVIEW
12.2 5-DOSES
12.3 10-DOSES
12.4 20-DOSES
12.5 50-DOSES
12.6 OTHERS
13 GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET, BY END USER
13.1 OVERVIEW
13.2 VETERINARY HOSPITALS
13.3 ANIMAL FARMA AND HUSBANDRY
13.4 VETERINARY CLINICS
13.5 LABORATORIES
13.6 OTHERS
14 GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 RETAIL SALES
14.3.1 DRUGS STORES
14.3.2 HOSPITAL AND CLINICS BASED PHARMACIES
14.3.3 ONLINE PHARMACY
14.3.4 OTHERS
14.4 OTHERS
15 GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.5 MERGERS & ACQUISITIONS
15.6 NEW PRODUCT DEVELOPMENT & APPROVALS
15.7 EXPANSIONS
15.8 REGULATORY CHANGES
15.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
16 GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET, BY GEOGRAPHY
GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
16.2 EUROPE
16.2.1 GERMANY
16.2.2 FRANCE
16.2.3 U.K.
16.2.4 ITALY
16.2.5 SPAIN
16.2.6 RUSSIA
16.2.7 TURKEY
16.2.8 BELGIUM
16.2.9 REST OF EUROPE
16.3 ASIA-PACIFIC
16.3.1 JAPAN
16.3.2 INDIA
16.3.3 AUSTRALIA
16.3.4 THAILAND
16.3.5 REST OF ASIA-PACIFIC
16.4 MIDDLE EAST
16.4.1 SAUDI ARABIA
16.4.2 UAE
16.4.3 ISRAEL
16.4.4 SOUTH AFRICA
16.4.5 TURKEY
16.4.6 REST OF MIDDLE EAST
16.5 SOUTH AMERICA
16.5.1 PERU
16.5.2 COLOMBIA
16.5.3 OTHERS
16.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
17 GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET, SWOT AND DBMR ANALYSIS
18 GLOBAL BOVINE EPHEMERAL FEVER VACCINES MARKET, COMPANY PROFILE
18.1 GREEN CROSS VETERINARY PRODUCTS CO., LTD.
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 ZOETIS INC.
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 OBP VACCINES
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 KYOTO BIKEN LABORATORIES, INC
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 KBNP
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
19 RELATED REPORTS
20 CONCLUSION
21 QUESTIONNAIRE
22 ABOUT DATA BRIDGE MARKET RESEARCH
